Vitiligo is a well-known side effect in patients undergoing treatment for melanoma with either anti-PD-1 immunotherapy or B-Raf (BRAF)/mitogen-activated protein kinase (MEK)-directed targeted therapy.1 Here, MAP2K7 is linked to melanoma.